Canine acanthomatous ameloblastomas (CAA), analogs of human ameloblastoma, are oral tumors of odontogenic origin for which the genetic drivers have remained undefined. By whole-exome sequencing, we have now discovered recurrent HRAS and BRAF activating mutations, respectively, in 63% and 8% of CAA. Notably, cell lines derived from CAA with HRAS mutation exhibit marked sensitivity to MAP kinase (MAPK) pathway inhibitors, which constrain cell proliferation and drive ameloblast differentiation. Our findings newly identify a large-animal spontaneous cancer model to study the progression and treatment of RAS-driven cancer. More broadly, our study highlights the translational potential of canine cancer genome sequencing to benefit both humans and their companion animals.
Introduction
As do humans, domestic dogs develop spontaneous cancers with genetic and environmental influences 1, 2 . Common cancers in dogs include lymphoma, osteosarcoma, mammary carcinoma, hemangiosarcoma, oral melanoma, and mast cell tumors, among others. Canine cancers display strong similarities to their human counterparts in histopathology, tumor genetics, and clinical behavior. With millions of pet dogs cared for into old age (and about half developing cancer), dogs offer a largely untapped resource for new cancer insight, as well as advantageous models for preclinical testing 3 . Toward this end, and enabled by the completion of the canine reference genome 4 , incipient efforts are underway to systematically sequence canine cancer genomes [5] [6] [7] .
Canine acanthomatous ameloblastomas (CAAs) are odontogenic tumors of the jaw, thought to represent the counterpart of human ameloblastoma (acanthomatous histologic variant) 8 . CAAs share with human ameloblastoma their histology, propensity to infiltrate bone while rarely metastasizing, and presumptive origin from the ameloblast (enamel secreting) cell lineage 9 , though non-odontogenic origins have also been speculated. CAAs are found across diverse dog breeds and notably occur far more commonly than do human ameloblastomas 10 . Current recommended treatment of CAA is surgical excision. While human ameloblastomas harbor driver mutations in the mitogen-activated protein kinase (MAPK) pathway (including BRAF, KRAS, NRAS, HRAS and FGFR4) and Hedgehog pathway (SMO) 11, 12 , the drivers of CAA have not been known.
Results

Frequent HRAS mutations in CAA
To identify cancer-driving mutations in CAA, we carried out whole-exome sequencing (WES) of formalin-fixed paraffin-embedded (FFPE) tumor tissue from 16 prototypical CAA cases from diverse breeds (Fig. 1a, b and Tables 1, S1). We then used PCR/Sanger sequencing to confirm select mutations in the discovery set plus additional specimens (together totaling 20 CAA cases). Because we lacked matched normal tissue (useful to exclude personal germline single-nucleotide variants (SNVs)), our analysis focused on the canine orthologs of 600 known human cancer genes and, within that set, known mutation "hotspot" sites (Fig. S1 and Tables S2,  S3 ).
Strikingly, 11 of the 20 (55%) CAA cases carried activating HRAS mutations (10 HRAS-Q61R and 1 HRAS-G13R), and 2 of the 20 (10%) carried activating BRAF mutations (BRAF-V595E, orthologous to the human BRAF-V600E driver mutation) (Fig. 1c-e and Tables 1,  S4 ). In the seven remaining CAA cases, no driver hotspot mutation was identified. HRAS and BRAF mutation allele frequencies (range 11-46%; mean 29%) were consistent with somatically acquired mutations (i.e., admixed with normal stroma), which we confirmed in three CAA cases by laser microdissection (and PCR/Sanger sequencing) of separate tumor epithelium and stroma (Fig. S2 ). In distinction from human ameloblastomas, where BRAF and SMO mutations are preferentially localized, respectively, to mandibular and maxillary tumors 12 . c Integrated Genome Viewer display of mapped reads from WES of CAA case harboring HRAS-Q61R mutation. Red and blue reads map to plus and minus strands, respectively; only a subset of mapped reads is shown. WES was done on 16 CAA samples; while this was an exploratory study, sample sizes of 10-15 should provide 80% power to identify driver mutations if present at ≥20-30% frequency. Genomic DNA was extracted from CAA FFPE tissue scrolls using the Qiagen (Germantown, MD, USA) DNA FFPE Tissue Kit. WES was done using the Agilent (Santa Clara, CA, USA) SureSelect Canine All Exon Kit, following modifications recommended for FFPE-derived DNA samples. Barcoded WES libraries were sequenced (101 bp × 2) on an Illumina HiSeq2500 or 4000 instrument (Stanford Genome Sequencing Service Center) to an average 116× mean base pair coverage. Raw reads were aligned to the dog genome (CanFam3.1) using BWA 21 . Single-nucleotide variants (SNVs) were called using SAMtools 22 mpileup and, in the absence of matched normal, restricted to 597 canine gene orthologs of known human cancer genes (the union of Cancer Gene Census and FoundationOne gene lists) (Table S2 ). SNVs were annotated using the Ensembl Variant Effect Predictor 23 . Subsequently, SNVs were filtered to exclude known germline variants (SNPs) and to retain only those SNVs with High evidence (read depth ≥20; minor allele frequency 20-50%) and High consequence (missense, stop-gain, or splice donor/acceptor variants), yielding 171 SNVs (in 91 genes) across 16 tumors (Table S4 ). To further distinguish likely somatically acquired SNVs from personal germline SNPs, we focused only on those SNVs occurring at the orthologous position of known human cancer hotspot mutations 24 (Table S3 ), determined from the Catalogue of Somatic Mutations in Cancer (COSMIC) 25 . Finally, we performed manual inspection of reads spanning HRAS-61, HRAS-13, and BRAF-595, identifying one additional HRAS-Q61R case (CAA-20) with mutant allele frequency 11%, missed by the automated SNV caller. All WES data are available from NCBI SRA (accession PRJNA516699). d Sanger sequencing validation of HRAS-Q61R and BRAF-V595E mutations in two different CAA cases. All HRAS and BRAF mutations identified by WES were confirmed by PCR amplification followed by Sanger sequencing. The PCR/sequencing primers used are available in Table S7 . e Summary of HRAS and BRAF mutations across the 20 CAA FFPE and 4 fresh tissue cases surveyed; anatomic site indicated (see color key). Note, no HRAS or BRAF mutations were identified outside of the mutation hotspots in any of the samples and BRAF mutations occurred in both anatomic sites (Fig.  1e ), and no canine SMO mutations were identified. We also used the WES reads to infer DNA copy number alterations (CNAs); all but one CAA case exhibited relatively flat CNA profiles ( Fig. S3 ).
HRAS mutations confer sensitivity to MAPK pathway inhibition
To further investigate MAPK pathway-driven CAA, we generated immortalized cell lines from fresh tissue of four additional CAA cases, by conditional reprogramming (i.e., culturing cells with Rho-associated protein kinase (ROCK) inhibitor and irradiated fibroblast conditioned media) 13 . All four cell lines harbored the HRAS-Q61R activating mutation ( Fig. 2a, b and Table 1 ). Testing two of the CAA (HRAS-Q61R) cell lines, both were highly sensitive (at low nanomolar concentrations) to mitogen-activated extracellular signal-regulated kinase (MEK) inhibition by GDC-0623, an allosteric MEK inhibitor that also blocks feedback-mediated RAF/MEK activation 14 (Fig. 2c ). Inhibition of canine MEK activity was confirmed by phospho-extracellular signal-regulated kinase (phospho-ERK) western blot (Fig. 2d) . To exclude nonspecific cell toxicity of GDC-0623, we tested CAMA-1 breast cancer cells, which we found consistent with published reports 15 to be insensitive to MEK inhibition (Fig. 2c) . CAA (HRAS-Q61R) cells were also highly sensitive to the MEK inhibitor cobimetinib (GDC-0973), though it has been reported less effective against mutant-RAS than mutant-BRAF-driven tumor models 14 , as well as the ERK inhibitor SCH772984, reported effective against RASdriven cancer models 16 (Fig. 2c) .
Interestingly, MEK inhibition not only blocked CAA (HRAS-Q61R) cell proliferation but also led to cell flattening reminiscent of cellular senescence and/or terminal differentiation (Fig. 3a, b) . To further investigate, we profiled gene expression following MEK inhibition by GDC-0623 (vs. vehicle control). Notably, the genes upregulated by MEK inhibition were significantly enriched for tooth development genes 17 (P < 0.0001; Gene Set Enrichment Analysis) ( Fig. 3c and Table S5 ), supporting an odontogenic origin for CAA. Among these, the ameloblast-specific gene AMTN (Amelotin) 18 was upre-gulated~5000-fold (Table S6 ).
Discussion
Here, by WES of CAA FFPE and subsequent fresh tissue specimens, we have in total identified HRAS activating mutations in 63% of cases (15 of 24) and BRAF activating mutations in 8% of cases (2 of 24). Together, over two thirds (71%) of CAA cases carry activating MAPK pathway mutations that should be targetable by existing Food and Drug Administration-approved or investigational (Table S1 ) were established by conditional reprogramming following published methods 26 . Briefly, fresh tumor tissue was minced, and then cells were disaggregated by Collagenase/Hyaluronidase using StemCell Technologies (Vancouver, BC, Canada) reagents and protocols, followed by Trypsin and Dispase. Cells were then filtered through a 40-µM cell strainer and plated in Complete F medium (conditioned by irradiated J2 strain mouse Swiss-3T3 fibroblasts and containing 10 µM ROCK inhibitor (Y-27632)). Cells were passaged by trypsinization, with no appreciable change in growth properties over >20 passages. Cell lines are available from J.R. P. upon request. drugs. Indeed, we demonstrate that CAA cells carrying HRAS-Q61R mutation are highly sensitive to MEK and ERK inhibition. Interestingly, MEK inhibition not only constrains cell proliferation but also appears to drive ameloblast differentiation, noted by the 5000-fold induction of the ameloblast-specific AMTN transcript. While most CAA cases harbored HRAS or BRAF mutations, 29% (7 of 24) carried neither. Because we did not have matching normal DNA (helpful in distinguishing somatic mutations from personal germline variants), we limited our analysis to the canine orthologs of known human cancer gene hotspot mutations. Future studies that include matching normal DNA may reveal additional CAA-driver mutations, either within or outside the MAPK pathway, and should inform mutational burdens as well as signatures suggestive of particular mutational processes.
Additionally, while CAA cells with HRAS-Q61R showed sensitivity to MEK and ERK inhibitors, it remains to be determined whether single-agent therapies will be effective in vivo. For example, with human BRAF-mutant melanomas treated by BRAF inhibition, acquired resistance often develops, while dual BRAF and MEK inhibition has shown improved efficacy 19 .
Importantly, our findings newly identify a large-animal spontaneous tumor model of RAS/RAF-driven cancer, valuable for preclinical testing of MAPK pathway inhibitors. CAA could model MAPK pathway dependence, inhibitor sensitivity, and resistance not only for human ameloblastoma but potentially also for other RAS/RAF mutation-driven human cancers (e.g., thyroid cancer, lung cancer, pancreatic cancer, and melanoma). Surgical excision remains the mainstay treatment of human ameloblastoma, though targeted therapies (particularly MAPK pathway inhibitors) show promise 20 , and regimens might be optimized through preclinical testing in dogs. Our findings also offer more immediate translation in the management of CAA, for example, for compassionate use of MEK/ERK inhibitors in pet dogs that are not surgical candidates (e.g., because of tumor location, extent, or comorbidities). More broadly, our study demonstrates the feasibility, importance, and promise of dog genome sequencing and comparative oncogenomics studies and the commensal benefit to both humans and their companion animals.
